Clinical trial

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

NCT01761318

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Liraglutide Normalized identity: liraglutideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Liraglutide - Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-11-01

PhasePHASE4

Conditions

Diabetes Mellitus Type 2candidate · MONDO: type 2 diabetes mellitus

Metabolic Syndromeverified · MONDO: abdominal obesity-metabolic syndrome

Cardiovascular Diseaseverified · MONDO: cardiovascular disorder

Diastolic Dysfunctionunresolved

Fatty Liververified · MONDO: fatty liver disease

Interventions

LiraglutideDRUG · verified · RxNorm: liraglutide

Liraglutide - PlaceboDRUG

Sponsors & collaborators

Leiden University Medical Centerlead sponsor

Novo Nordisk A/Scollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01761318 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.